M. Rogers, S. Gordon, H. Benford, F. Coxon, S. Luckman et al., Cellular and molecular mechanisms of action of bisphosphonates, Cancer, vol.20, issue.52, pp.2961-2978, 2000.
DOI : 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L

J. Green and P. Clezardin, Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis, American Journal of Clinical Oncology, vol.25, pp.3-9, 2002.
DOI : 10.1097/00000421-200212001-00002

D. Amin, S. Cornell, S. Gustafson, S. Needle, J. Ullrich et al., Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis, J Lipid Res, vol.33, pp.1657-1663, 1992.

J. Bergstrom, R. Bostedor, P. Masarachia, A. Reszka, and G. Rodan, Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase, Archives of Biochemistry and Biophysics, vol.373, issue.1, pp.231-241, 2000.
DOI : 10.1006/abbi.1999.1502

K. Thompson, J. Dunford, F. Ebetino, M. Rogers, E. Van-beek et al., Identification of a Bisphosphonate That Inhibits Isopentenyl Diphosphate Isomerase and Farnesyl Diphosphate Synthase, Biochemical and Biophysical Research Communications, vol.290, issue.2, pp.869-873108, 1999.
DOI : 10.1006/bbrc.2001.6289

H. Benford, J. Frith, S. Auriola, J. Monkkonen, and M. Rogers, Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs, Mol Pharmacol, vol.56, pp.131-140, 1999.

S. Luckman, D. Hughes, F. Coxon, R. Graham, G. Russell et al., Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras, Journal of Bone and Mineral Research, vol.8, issue.Suppl 4, pp.581-589, 1998.
DOI : 10.1359/jbmr.1998.13.4.581

T. Iguchi, Y. Miyakawa, K. Yamamoto, M. Kizaki, and Y. Ikeda, Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway, Cellular Signalling, vol.15, issue.7, pp.719-727, 2003.
DOI : 10.1016/S0898-6568(03)00007-X

J. Fisher, M. Rogers, J. Halasy, S. Luckman, D. Hughes et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, Proceedings of the National Academy of Sciences, vol.14, issue.5, pp.133-138, 1999.
DOI : 10.1023/A:1012157212793

K. Sawada, K. Morishige, M. Tahara, R. Kawagishi, Y. Ikebuchi et al., Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho, Cancer Res, vol.62, pp.6015-6020, 2002.

C. Denoyelle, L. Hong, J. Vannier, J. Soria, and C. Soria, New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects, British Journal of Cancer, vol.88, issue.10
DOI : 10.1038/sj.bjc.6600925

F. Coxon, M. Helfrich, R. Van-'t-hof, S. Sebti, S. Ralston et al., Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298, Journal of Bone and Mineral Research, vol.108, issue.8, pp.1467-1476, 2000.
DOI : 10.1359/jbmr.2000.15.8.1467

E. Van-beek, C. Lowik, and S. Papapoulos, Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors, Bone, vol.30, issue.1, pp.64-70, 2002.
DOI : 10.1016/S8756-3282(01)00655-X

G. Oades, S. Senaratne, I. Clarke, R. Kirby, and K. Colston, Nitrogen Containing Bisphosphonates Induce Apoptosis and Inhibit the Mevalonate Pathway, Impairing Ras Membrane Localization in Prostate Cancer Cells, The Journal of Urology, vol.170, issue.1, pp.246-252, 2003.
DOI : 10.1097/01.ju.0000070685.34760.5f

S. Senaratne, J. Mansi, and K. Colston, The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells, British Journal of Cancer, vol.90, issue.9, pp.1479-1486, 2002.
DOI : 10.1038/sj.bjc.6600297

S. Virtanen, H. Vaananen, P. Harkonen, and P. Lakkakorpi, Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway, Cancer Res, vol.62, pp.2708-2714, 2002.

F. Saad, Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid, Seminars in Oncology, vol.29, issue.6 Suppl 21, pp.19-27, 2002.
DOI : 10.1053/sonc.2002.37418

M. Smith, F. Mcgovern, A. Zietman, M. Fallon, D. Hayden et al., Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer, New England Journal of Medicine, vol.345, issue.13, pp.948-955, 2001.
DOI : 10.1056/NEJMoa010845

S. Boissier, M. Ferreras, O. Peyruchaud, S. Magnetto, F. Ebetino et al., Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases, Cancer Res, vol.60, pp.2949-2954, 2000.

M. Lee, E. Fong, F. Singer, and R. Guenette, Bisphosphonate treatment inhibits the growth of prostate cancer cells, Cancer Res, vol.61, pp.2602-2608, 2001.

E. Lerner, Y. Qian, M. Blaskovich, R. Fossum, A. Vogt et al., Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes, Journal of Biological Chemistry, vol.270, issue.45
DOI : 10.1074/jbc.270.45.26802

T. Mcguire, Y. Qian, A. Vogt, A. Hamilton, and S. Sebti, Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation, Journal of Biological Chemistry, vol.271, issue.44, pp.27402-27407, 1996.
DOI : 10.1074/jbc.271.44.27402

O. Cussenot, P. Berthon, R. Berger, I. Mowszowicz, A. Faille et al., Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene, J Urol, vol.146, pp.881-886, 1991.

P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. Mcmahon et al., New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, JNCI Journal of the National Cancer Institute, vol.82, issue.13, pp.1107-1112, 1990.
DOI : 10.1093/jnci/82.13.1107

A. Awad, H. Williams, and C. Fink, Effect of phytosterols on cholesterol metabolism and MAP kinase in MDA-MB-231 human breast cancer cells, The Journal of Nutritional Biochemistry, vol.14, issue.2, pp.111-119, 2003.
DOI : 10.1016/S0955-2863(02)00274-7

E. Corey, L. Brown, J. Quinn, M. Poot, M. Roudier et al., Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer, Clin Cancer Res, vol.9, pp.295-306, 2003.

D. Crick, D. Andres, and C. Waechter, Novel Salvage Pathway Utilizing Farnesol and Geranylgeraniol for Protein Isoprenylation, Biochemical and Biophysical Research Communications, vol.237, issue.3, pp.483-487, 1997.
DOI : 10.1006/bbrc.1997.7145

R. Lobell, D. Liu, C. Buser, J. Davide, E. Depuy et al., Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I, Mol Cancer Ther, vol.1, pp.747-758, 2002.

S. Holstein, D. Cermak, D. Wiemer, K. Lewis, and R. Hohl, Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase, Bioorganic & Medicinal Chemistry, vol.6, issue.6, pp.687-694, 1998.
DOI : 10.1016/S0968-0896(98)00034-0

S. Ownby and R. Hohl, Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis, Lipids, vol.277, issue.7, pp.751-759, 2003.
DOI : 10.1007/s11745-003-1123-8

C. Allal, G. Favre, B. Couderc, S. Salicio, S. Sixou et al., RhoA Prenylation Is Required for Promotion of Cell Growth and Transformation and Cytoskeleton Organization but Not for Induction of Serum Response Element Transcription, Journal of Biological Chemistry, vol.275, issue.40, pp.31001-31008, 2000.
DOI : 10.1074/jbc.M005264200

J. Dunford, K. Thompson, F. Coxon, S. Luckman, F. Hahn et al., Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J Pharmacol Exp Ther, vol.296, pp.235-242, 2001.

J. Fisher, G. Rodan, and A. Reszka, Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway, Endocrinology, vol.141, issue.12, pp.4793-4796, 2000.
DOI : 10.1210/endo.141.12.7921